Miia Turpeinen

Dr. Miia Turpeinen


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2008 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
UZUlrich M. Zanger
Ulrich M. Zanger
MTMiia Turpeinen
Miia Turpeinen
KKKathrin Klein
Kathrin Klein
Matthias SchwabMatthias Schwab
Matthias Schwab

11 July 2008 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
OPOlavi Pelkonen
Olavi Pelkonen
MTMiia Turpeinen
Miia Turpeinen
JHJukka Hakkola
Jukka Hakkola
PHPaavo Honkakoski
Paavo Honkakoski
JHJanne Hukkanen
Janne Hukkanen
HRHannu Raunio
Hannu Raunio

1 March 2010 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
SASébastien Anthérieu
Sébastien Anthérieu
CCChristophe Chesné
Christophe Chesné
RLRuoya Li
Ruoya Li
SCSandrine Camus
Sandrine Camus
ALAgustin Lahoz
Agustin Lahoz
AGAndré Guillouzo
André Guillouzo
HepaRG cells possess the unique property to differentiate in vitro and to express various functions of mature hepatocytes, including the major cytochromes P450 (P450s). In the present study, we carefully analyzed mRNA expression and activity of the major P450s and their responsiveness to three prototypical inducers, phenobarbital, rifampicin, and omeprazole, in differentiated HepaRG cell cultures over a 4-week period after low and high seeding. Only minor differences were observed in P450 activities when measured by two cocktails of probe substrates, probably related to the choice and/or concentration of substrates. Similar results were obtained from the two cell seeding conditions. Expression and activities of several P450s were dimethyl sulfoxide-dependent. However, basal P450 expression and activities as well as their responsiveness to the prototypical inducers were well maintained over the 4-week period, and a good correlation was observed between transcript levels and corresponding activities. Thus, CYP1A2, CYP2B6, and CYP3A4 were found to accurately respond to their respective prototypical inducers, i.e., omeprazole, phenobarbital, and rifampicin. Likewise, basal expression of several phase II enzymes, transporters, and nuclear receptors, and response to inducers were also well preserved. More genes were found to be induced in HepaRG cells than in primary human hepatocytes, and no marked variation was noticed between the different passages. Taken together, these data support the conclusion that HepaRG cells represent a promising surrogate to primary human hepatocytes for xenobiotic metabolism and toxicity studies.

1 June 2005 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MTMiia Turpeinen
Miia Turpeinen
ATA Tolonen
A Tolonen
JUJ Uusitalo
J Uusitalo
JJJ Jalonen
J Jalonen
OPO Pelkonen
O Pelkonen
KLK Laine
K Laine

17 April 2009 in Pharmacogenomics
Verified
Journal Article
Closed access
AGAna M Gomes
Ana M Gomes
SWStefan Winter
Stefan Winter
KKKathrin Klein
Kathrin Klein
MTMiia Turpeinen
Miia Turpeinen
ESElke Schaeffeler
Elke Schaeffeler
UZUlrich M Zanger
Ulrich M Zanger
Aims: NADPH:CYP oxidoreductase (POR) is an essential component of several enzyme systems, including the microsomal CYP monooxygenases. We investigated genetic and nongenetic POR variability and its impact on drug-oxidation activities in human liver microsomes. Material and methods: POR mRNA, protein and activity, as well as ten major drug-oxidation activities, were measured in the microsomes of 150 Caucasian surgical liver samples. Matrix-assisted laser desorption/ionisation-time of flight mass spectrometric assays were established to determine the frequency of 46 selected POR SNPs. Multivariate log-linear regression models, including main effects and two-way interaction terms, and analyses of variance were used to identify statistically significant relationships. Results: POR phenotypes were less variable within the study population as compared with CYP phenotypes. Intronic SNPs g.18557G>A (intron 2), g.25676C>T (intron 3) and g.30986 G>A (intron 10) were associated with various drug-oxidation activities...

25 February 2005 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
OPOlavi Pelkonen
Olavi Pelkonen
MTMiia Turpeinen
Miia Turpeinen
JUJouko Uusitalo
Jouko Uusitalo
ARArja Rautio
Arja Rautio
HRHannu Raunio
Hannu Raunio